Cellular Biomedicine — Investor Presentation (August 2020)

20 slides from Cellular Biomedicine's investor presentation, Aug 28, 2020

Slide 1: Building a Competitive Cell Therapy Company
"aon pan 2 e at - ee . Building a Competitive ( Cell Therapy eapeiiie for sgauuersatont ; # ie | ee S mitt ¢ oa ¢ % CBMG Cellular Biomedicine Group pS
Slide 2: Safe Harbor
Safe Harbor 7eamc Statements in his presentation relating to plans, strategies, ends, specie activites, vestments, and other statements that ar not ‘descriptions of historical facts, including our expectations regarding our Immuno-oncology and regenerative medicine ence als, may 'e fonearaooking sta
Slide 3: CBMG Core Strategy
CBMG Core Strategy Develop Key Bui Strive for Speedy Delivery of Quality Drugs to Pat ling Blocks: Relevant and strong RnD expertise in. cell and gene therapies. Aim for potentially best in class and/or among first three to the market Translation medicine for target patient population selection & un
Slide 4: Seeking BLA in China and Partnership in the US
Seeking BLA in China and Partnership in the US A CBMG IND Clinical China manurectave Submission // Development NMPA Filing © 3 - =] (ml Investigator ite Ta qT) ee Positive =» US IND .) Clinical ) US Early Safety Results ‘Submission // Development FDA Filing & POC Readout a.
Slide 5: Investigator Initiated Trial (IIT) in China
Investigator Initiated Trial (IIT) in China [eam > Only cell, gene and stem cell therapies are allowed to explore IIT path in China, and encouraged by both NMPA and NHC. > The sponsor and Pls work together to obtain scientific board and IRB approval. The hospital then submits the trial information t
Slide 6: Rich Patient Pool, Favorable Hospitals & Experienced PIs
Rich Patient Pool, Favorable Hospitals & Experienced Pls FcBMc China has ~ 5 million new cancer patients every year The specialized hospitals offer a large patient pool which is unmatched in the US. For example, Shanghai Chest Hospital treats over 30k new lung cancer patients per year, with ~5k pati
Slide 7: CBMG Pipeline
cBmG STEM CELL THERAPY PRODUCT INDICATION PRECUNICAL PHASE PHASE? PHASE hamec Alooin* te) OA —O—— TOA Ane testis ‘nto. asdogoes IMMUNO-ONCOLOGY THERAPY provuct INDICATION PRECLINICAL PHASE PHASE ‘Anti-BCMA CAR: MM om CART | angico20cAR WVRNL 0 ‘AetsCD18,CD208ICAR NHL TERT | apereRT Hee Ti fontow/xer
Slide 8: Anti-BCMA CAR (C-CAR088) is a 2nd generation 4-1BB anti-BCMA CAR
Anti-BCMA CAR (C-CAR088) is the 2nd a generation 4-1BB anti-BCMA CAR with Human scFv &.C BMG + scFv of C-CAR088 specific target epitome cluster E3 in BCMA extra-cellular domain 1 dl 20 30° z 40 Sa MEQHAGQCSQNEYEDSELEACTPOOLRCSSNTPELTCORYCNASUINGVAGINA z : aay | ez termi domain 6442-54 sulfide Bound
Slide 9: C-CAR088 Shows Robust in vitro Anti-tumor Activity
C-CAR088 Shows Robust in vitro Anti-tumor Activity Eonar Bera Gre Anti-BCMA CAR Expression pat BCMA Cell Killing Assays NHO2s-8cMA Hi BCMA Expression on Target Cells map wnaz0-0cuar moss. rervew MM.ts TA BY tor Zor woe EtfectorTarget TH St wT Bea wT Effector-Target TH sr ior wi ot Effector Target
Slide 10: Phase I Study in R/R Multiple Myeloma (IIT)
Phase | Study in R/R Multiple Myeloma (IIT) 7eemc = wool ceanins ean qf = _ | SS ~ <1 oon oss Fest incl reponse asasoment 3+8 Dose Escalation study status wees E> ez» a= > zy Key Egy Ctra Salaty Assessment, Rate of dose SSterSyens soe fran toes ncames ard sererty + et xpress BMA ivetraneme-ort asa o
Slide 11: Summary for C-CAR088
Summary for C-CAR088 Fi CBMG > In preclinical studies, C-CARO88 shows strong antitumor activity both in vitro & in vivo. » No Grade 4 or higher CRS was observed in 17 patients. No Grade 2 or higher neurotoxicity and DLTs observed. Cytopenia mostly related to Cy/Fiu lymphodepletion > 100% ORR in 17 p
Slide 12: In vitro and in vivo Activity of Anti-CD20-CD19 Bi-specific CAR (C-CAR039)
In vitro and in vivo Activity of Anti-CD20-CD19 Feamc Bi-specific CAR (C-CAR039) ‘C-CAR039 cell activation and cytokine release after co-cultured with target cells Cell Killing Experiment on Target Cell Lines ‘A.ELISAID detect secretion vet FN nthe co-utre superatant 2. ow efoto etc Be upreptesexpes
Slide 13: C-CAR039 Phase I Study in r/r B-NHL (IIT)
C-CAR039 Phase 1 Study in r/r B-NHL (IIT) / BMG Dose Escalation of CAR+T Cells E-naa— (range: + 20% ofthe target dose} Key Eligibility Criteria DLBCLFLMCL + Either CD19 or C020, positive disease + No active CNS involvement deeddyy yd y 4 4 Incidence and severity of treatment-emergent ‘adverse events
Slide 14: Summary for C-CAR039
Summary for C-CAR039 Fi CBMG > C-CAR0339 is a novel bi-specific CAR-T, targeting both CD19 and CD20. > C-CAR039 showed reactivity against both single positive and double positive tumor in vitro and in vivo, can potentially be the best-in-class of CAR-T cell therapies for B cell malignancies as it ad
Slide 15: Development of TIL as a Treatment for Immunogenic Solid Cancers
Development of TIL as a Treatment ToR for Immunogenic Solid Cancers 7CBMG + TiL therapy, a potent and safe treatment for immunogenic cancers Somatic mutation burden by cancer + Multiple TIL manufacturing processes LLY AB vA ye ’ AMM dlaticattlidlg available if sjanenuelleneapeeden de + Traditional T
Slide 16: Benefits of TIL Technology
its of TI chnology TIL technology is based on a patents own TL which astray muitwaiot targeting artgens Specie to patent's tumor ‘Enhancing T-cell number and potency Tit solated trom a resected tuner are expanded {a several bilon sets ex vvo, enabing Seministaton of potent, highly activated cals. Co
Slide 17: Lung Cancer TIL Study Design & Patient Disposition
Lung Cancer TIL Study Design & Patient Deposition: FeBmc rir NSCLC Patients Post Nivolumab Treatment Son Samana Ge PS aay pevcblimenitn fori manulacto. sme Te + Noam 240 mg V evs x4 doves Sree 1 IPRcinca bent thn say on nolomab deraiy | fori : Sa + fPderS0 ih enargnginew esionbator a2 BNF. Seiten t0
Slide 18: TIL Therapy Clinical Results in Advanced NSCLC that Failed Nivolumab Therapy
TIL Therapy Clinical Results in Advanced NSCLC ae that Failed Nivolumab Therapy £CBMG "Tumor response before and after TIL ‘Summary 1. Til can be produced in 95% (19/20) of NSCLC patients. 2. Durable responses were observed with TIL therapy. BORR 20% * 2:¢R ongoing, 1 PR, 2UPR, and 1 UPR (his one is
Slide 19: CBMG TIL Strategy
CBMG TIL Strategy 7eemc > Improve the next TIL trial by addressing key issues from previous studies > Invest in TIL process development in both US and China > Will sponsor and initiate TIL‘ trial in the US for stage IIIB and IV NSCLC patients (excluding EGFR mutation, ALK fusion) refractory to anti-
Slide 20: Saving Life, Revitalizing Life
Saving Life Revitalizing Life www.cellbiomedgroup.com

Cellular Biomedicine Group — Investor Presentation (August 2020) on 6ix

Cellular Biomedicine — Investor Presentation (August 2020)

Slide 1: Building a Competitive Cell Therapy Company

Slide 2: Safe Harbor

Slide 3: CBMG Core Strategy

Slide 4: Seeking BLA in China and Partnership in the US

Slide 5: Investigator Initiated Trial (IIT) in China

Slide 6: Rich Patient Pool, Favorable Hospitals & Experienced PIs

Slide 7: CBMG Pipeline

Slide 8: Anti-BCMA CAR (C-CAR088) is a 2nd generation 4-1BB anti-BCMA CAR

Slide 9: C-CAR088 Shows Robust in vitro Anti-tumor Activity

Slide 10: Phase I Study in R/R Multiple Myeloma (IIT)

Slide 11: Summary for C-CAR088

Slide 12: In vitro and in vivo Activity of Anti-CD20-CD19 Bi-specific CAR (C-CAR039)

Slide 13: C-CAR039 Phase I Study in r/r B-NHL (IIT)

Slide 14: Summary for C-CAR039

Slide 15: Development of TIL as a Treatment for Immunogenic Solid Cancers

Slide 16: Benefits of TIL Technology

Slide 17: Lung Cancer TIL Study Design & Patient Disposition

Slide 18: TIL Therapy Clinical Results in Advanced NSCLC that Failed Nivolumab Therapy

Slide 19: CBMG TIL Strategy

Slide 20: Saving Life, Revitalizing Life